Latvia vs Panama: Access to anti-retroviral drugs, female
Latvia
54.0%
in 2024
Panama
55.0%
in 2024
Latvia rank
114th
Panama rank
111th
Access to anti-retroviral drugs, female over time
- Latvia
- Panama
How they compare
Panama currently reports 55.0% against 54.0% in Latvia, a difference of 1.0%.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Panama ahead.
Latvia ranks 114th and Panama ranks 111th of 141 countries.
Across the 3 decades both report, Latvia averaged higher in 1 and Panama in 2.
Head to head by decade
| Decade | Latvia | Panama | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 2.5% | 16.9% | 14.4% | Panama |
| 2010s | 20.4% | 40.8% | 20.4% | Panama |
| 2020s | 51.2% | 50.0% | 1.2% | Latvia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Latvia or Panama?
- Panama, at 55.0% against 54.0% in Latvia as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Latvia and Panama?
- 1.0%, with Panama ahead.
- How many years of comparable data are there for Latvia and Panama?
- 25 years are reported by both, from 2000 to 2024.
- How do Latvia and Panama rank globally for access to anti-retroviral drugs, female?
- Latvia ranks 114th and Panama ranks 111th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.